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Abstract 
Introduction: Conjugated linoleic acid (CLA) has been shown to positively influence calcium and bone 
metabolism in experimental animals and cell culture, but there are limited human data available.  
Material and Methods: The study consisted of a double-blind, placebo-controlled trial in which 76 healthy post-
menopausal women (aged 55.1) were randomly assigned to receive daily either four capsules CLA G80 
containing 3.2 g isomer blend (50:50% cis-9, trans-11: trans-10, cis-12 isomers) or four capsules containing high 
oleic sunflower oil as placebo for 12 weeks. Urine and blood samples were collected at weeks 0 and 12 and were 
analyzed for biomarkers of calcium and bone metabolism and inflammatory markers (TNF-α and IL-6). Subjects 
completed 3-days dietary records during the trial, in weeks 0 (baseline), 6 and 12. 
Results: Supplementation with 3.2 g CLA isomer blend (50:50% cis-9,trans-11:trans-10,cis-12 isomers) for 12 
weeks had no significant effects on markers of bone formation (serum osteocalcin, bone-specific alkaline 
phosphatase) or bone resorption (urine C-telopeptide-related fraction of type 1 collagen degradation products), 
PTH, urinary calcium, urinary creatinine and CTP to creatinine ratio. And serum interleukine-6 did not change 
significantly over 12 weeks in postmenopausal women.  
Conclusion: Under the conditions tested in this double-blind, placebo-controlled trial in postmenopausal women, 
3.2 g CLA isomer blend (50:50% cis-9, trans-11: trans-10, cis-12 isomers) did not affect markers of bone 
metabolism and calcium.  
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Introduction 
Women normally spend one-third of their lives in 
postmenopausal phase1. Especially in the first decade 
after menopause, bone density loss is observed2. 
Shortage of ovarian hormones, particularly estrogen 
efficiency, is the most common cause in bone density 
loss after menopause. This factor exposes 
postmenopausal women to higher risk of osteoporosis3. 
In the elders, especially in women, it has been seen that 
osteoporosis due to bone density loss and high bone 
fragility lead to osteoporotic fractures4. 
Today, hormone therapy and inhibitory medicines of 
bone re-absorption are used in order to prevent and 
treat osteoporosis5. But, due to possible consequences 
of estrogen therapy such as breast cancer and 
endometrial adenocarcinoma, the adoption of this kind 
of treatment in postmenopausal is very low and only 
3% to 8% of the women accept this kind of treatment6. 
Prevention of osteoporosis is easier than its treatment. 
Nutrition and lifestyle management are used in order to 
minimize bone density loss, decrease the need for 
medication and prevent osteoporosis. The effect of 
nutritional interventions on bone density regulation is 
well known7. 
Over the past few years, there has been considerably 
much attention to biological benefits of conjugated 
linoleic acid (CLA) on health care8, for example anti-
obesity function in animals9-11 and humans12-17, anti-
cancer effects, anti-tumor effects18-21, the risk reduction 
of atherosclerosis22-25, reduction of  the risk factors of 
diabetes and high blood pressure26-27, energy 
metabolism, positive effects on immune performance28 
and anti-inflammatory properties29-32. New properties 
of conjugated linoleic acid (CLA) are the increase of 
immune functions and positive properties in formation 
of bone in animal models. 
Useful properties of conjugated linoleic acid (CLA) are 
not provided by diet lonely and there is need for food 
supplements. There are 28 different isomers in 
conjugated linoleic acid (CLA) which main form of 
this acid is found in food, cis-9 and trans-11 as it is 
called Rummenic Acid. This isomer is 90% of 
conjugated linoleic acid in food33. Health benefits of 
conjugated linoleic acid isomers are mainly related to 
two kinds of isomers cis-9, trans-11 and cis-12. 
According to previous studies, there is an incoherence 
which isomers of conjugated linoleic acid (CLA) is 
more effective on bone metabolic bone34. Recent 
surveys on animals show that conjugated linoleic acid 
(CLA) can minimize bone density loss by decreasing 
the level of prostaglandin E2 in the bone issue35-36. 
Prostaglandin E2 is synthesized from arachidonic acid 
by cyclophosphamide oxygenase enzyme and effects 
on bone metabolism. The restrain or stimulation in 
bone formation and re-absorption is dependent on the 
prostaglandin E2 concentration. It leads to increased 
insulin- like growth factor (IGF) at low levels and 
regulates protein expression to insulin- like growth 
factor (IGFBP) and thus stimulates bond 
formations37,38. In high doses, it causes restraining the 
synthesis of collagen, decreasing mRNA in the bone, 
restraining osteoblast function and finally decreases the 
formation and density of bones37. 
On one hand, increasing the age and on the other hand, 
decreasing estrogen in postmenopausal women along 
with increase in producing prostaglandin E2 and 
inflammatory cytokines such as Tumor necrosis factor 
alpha, interleukin-6 and beta 1 by immune cells39-42 
results to the increase the activity of osteoclast and 
bone re- absorption in postmenopausal43. These 
cytokines lead to increase cyclo-oxygenase expression 
2 in osteoblastic and the production of prostaglandin 
E244,45. On the other hand, conjugated linoleic acid 
(CLA) causes to increase the absorption of the 
calcium46,47. In previous studies, there are shown the 
decreasing effects of inflammatory cytokines activities 
by conjugated linoleic acid (CLA) in animal models48.  
Therefore, due to mentioned subject, the evidences 
about the effect of linoleic acid (CLA) on bone density 
and its metabolism in animal and human model are 
mysterious. On the other hand, there is not performed 
any survey based on this research in order to evaluate 
those effects on postmenopausal women. This survey is 
conducted to determine the supplementary effect of 
conjugated linoleic acid (CLA) with similar mixture 
from known isomers trans- 10, cis- 12, cis- 9, cis- 11 
on the bone mineral density, its metabolism and 
inflammatory indexes in healthy postmenopausal 
women.  
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Materials and Methods 
In this clinical trial 76 women in the age of 45-65 with 
at least one and maximum 10 years spent their 
menopause period and their body mass index were 20-
32 kg/m2, were studied. Exclusion criteria included 
sever osteoporosis (t score below -2.5 for hip and 
spine), bone disease, smoking, using alcohol and drugs, 
risk of fracture in recent three months, heart disease/ 
cardiovascular, hepatic disease, gastrointestinal, 
diabetes, hypothyroidism or hyperthyroidism, hormone 
therapy, dietary supplements for weight loss, omega 3 
supplements, medicines increasing bone, bone re-
absorption inhibitors, corticosteroids, anticonvulsant 
medicines and lipid and blood sugar lowering drugs. 
The written informed consents were obtained from all 
patients. Patients were randomly divided into two 
groups. First group received CLA supplement, daily 4 
capsules (each capsule 1 gram, totally 3.2 gram from 
the mixture 2 isomers cis- 9, trans- 11and trans- 9 and 
cis- 12 conjugated linoleic acid) and second group 
received some placebo, daily 4 capsules (each capsule 
was one gram containing sunflower oil with oleic 
acid). In this survey, the patients received the 
supplements and placebos for twelve weeks. CLA 
supplements used in this study were as follows: 
Clarinol G80 coated with a transparent gel coat 
containing 80% CLA (Dutch firm Lipid Nutrition 
Loders Croklaan B. V.). The patients were trained to 
take 3 capsules with each meal and 1 capsule before 
going to bed. 
The amounts of supplement acceptance by the patients 
were followed up by weekly calls and capsules 
remaining in packages were investigated at each visit, 
also patients were questioned about their problems. In 
these contacts, some issues and probable problems 
were addressed such as intolerance to supplements and 
other problems, probable change in use of foods, new 
disease and changes in physical activity. If any 
condition would happen, the patient would be omitted 
from the survey or his results would not be used for 
final analysis. At the end of the sixth week and twelfth 
week, the capsules were evaluated in terms of patients’ 
compliance, by counting remaining capsules.  
Blood Biochemical Assessment 
Serum concentrations of inflammatory markers, tumor 
necrosis factor alpha, interleukin 6, metabolic markers 
of the bone including bone alkaline phosphate, 
osteocalcin, C- urinary telopeptide (CTP) and 
parathyroid hormone (PHT), urinary calcium and 
urinary creatinine were measured. 
The levels of the serum IL-6 and TNF-α were 
investigated by ELISA which is the research kit 
(ELISA kit for human IL-6 and ELISA kit for human 
TNF-α, French Diaclon Firm). The measurement 
method sensitivity was lower than 2 pg.ml and 8 pg.ml, 
respectively. The accuracy of in-test in mentioned 
measurement was 5.3 and 6.1 respectively based on the 
percentage of in-test changes. C- telopeptide level in 
urine samples was determined by EIA and the bone- 
specific alkaline phosphate levels in serum were 
determined by using of immune enzymatic by research 
kits of Inc. IDS Bolton, UK. The sensitivity of 
measured method was 50 and 0.7 micrograms per liter. 
In-test accuracy in above measurement was 4.1 and 
4.9, respectively based on the variation coefficient.  
Serum osteocalcin levels were determined by using 
ELISA by research kits of IDS Inc. Bolton, England). 
The sensitivity of mention method was 0.5 ng.ml. The 
accuracy of in-test in mentioned measurement was 1.7 
based on the variation coefficient.  
The levels of serum parathyroid hormone (PTH) were 
measured by research kits of IDS Inc, Bolton, England 
by using of ELISA method. The sensitivity of mention 
method was 0.5pm.l. The accuracy of in-test in 
mentioned measurement was 5.5 based on the variation 
coefficient.  
Urinary creatinine level was measured by chemical 
colorimetric method (Pars Test Inc., Tehran, Iran). The 
sensitivity of mention method was 6 mg.dl. The 
accuracy of in-test in mentioned measurement was 1.2 
based on the variation coefficient. Urinary calcium was 
measured by chemical colorimetric method (Pars Test 
Inc., Tehran, Iran). The sensitivity of mention method 
was 0.2 mg.dl. The accuracy of in-test in mentioned 
measurement was 2.3 based on the variation 
coefficient. 
Statistical Methods 
To compare results, there were used t-test, Wilcoxson, 
Mann-Whitney U, Wilcoxson and ANOVA. The 
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meaningful level was considered as 0.05. There was 
used statistical software SPSS, version 16 to analysis 
data. 
Results 
First of all, 76 healthy postmenopausal women 
participated in this survey. There were 38 women in 
the placebo group and 38 women in the group of 
supplement receivers. The number of 4 women from 
the first group (2 persons because of headache, 2 
persons because of digestive problems or bellyache) 
and 5 women from second group (4 persons because of 
digestive problems and 1 person for traveling) were 
excluded from the survey. Therefore, total women 
participated in this survey were 67 persons. The 
amounts of capsules based on their counting were 
determined for first group (receiving CLA 
supplements) 85% and for second group (placebo 
group) 75%. 
Patients in two groups were similar in terms of age, 
time duration of menopause, height, body mass index, 
waist circumference, physical activity, systolic and 
diastolic blood pressure. In this survey, the changes 
related to bone mineral density and bone mineral 
content were not significant in two groups (Table 1). 
Tumor necrosis factor- alpha levels decreased after 12 
week consuming CLA supplements (1.97 pg.ml). But 
the rate of changes of IL-6 was not statistically 
significant (Table 2, Figure 1). 
 
Table 1: Bone mineral density in post-menopausal women initially 
and after 12 weeks. 
Body 
Composition 
Placebo( n=33) CLA supplement (n=34)  
Baseline After 12 
weeks 










09/0±1/1 09/0±1/1 09/0±08/1 09/0±09/1 0.2 
 
Changes in serum osteocalcin, serum bone alkaline 
phosphatase, PTH, C-telopeptide, urinary calcium, 
urinary calcium to creatinine ration were not 
statistically significant after 12 week consuming CLA 
supplements (Table 3).  
 
Table 2: Level of inflammatory markers in post-menopausal women 
initially and after 12 weeks. 
Inflammatory 
markers 
Placebo (n=33) CLA supplement (n=34) 
Baseline After 12 
weeks 
Baseline After 12 
weeks 
P value 
TNF-a (pg/ml) 9/3±8/7 4/3±7/8 7/3±8/6 2/2±7/4 0.00 
IL-6 (pg/ml) 8/0±95/0 7/0±12/1 7/0±11/1 6/0±03/1 0.07 
 
 
Table 3: Serum and urinary bone metabolism marker levels in post-




Placebo( n=33) CLA supplement (n=34) 
Baseline After 12 
weeks 
Baseline After 12 weeks P 
value  
Osteocalcin 





8±5/19 1/6±6/18 6±7/18 5/7±2/18 
0.75 
PTH (pmol/l) 
















03/0±39/0 04/0±35/0 02/0±35/0 01/0±25/0 
0.23 
Urinary CTP 
(µg/l) 1819±5/2903 2041±4/3402 1353±2702 1639±3339 
0.75 
CTP/Cr 
(µg/mmol) 106±1/236 9/208±266 9/128±5/250 7/116±1/234 
0.35 
Discussion 
In this survey, CLA supplement did not have any effect 
on urinary calcium in postmenopausal women 
participated in the survey. The only survey on the 
effect of CLA supplement on serum calcium and 
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urinary calcium is related to Doyle et al in 2005 and its 
results are similar to ours. In Kelly et al study, the 
calcium intestinal absorption in young mice were 
significantly increased by using of CAL supplements 
and food diet rich in fatty acid PUFA, n-3. But, this 
effect was not observed in food diet rich in fatty acid 
PUFA, n-6. CLA effects on bones are dependent on the 
amount of PUFA fatty acids in food diets. Both fatty 
acids n-3 and n-6 affect on cytokines, prostaglandins 
and, as a result, on the metabolism of bones. CLA is a 
competitive inhibitor with fatty acid PUFA, n-6.  It 
prevents elongation and reduces the availability of 
substrate for the enzyme cyclo-oxygenase and causes 
decreasing prostaglandin E2 production. In the present 
study, the amount of intake the fatty acid PUFA n-6 
was higher than fatty acid PUFA n-3. Lack of effect of 
CLA on bone metabolism markers and urinary 
calcium, despite of the decline in serum tumor necrosis 
factor-alpha, may be due to the inhibitory effect of high 
levels of fatty acid PUFA, N-6. 
 
 
Figure 1: Changes of TNF-a level in each group of our study. 
 
It is necessary to pay attention to special effects of 
CLA isomers as the lack of CLA effect on the bones 
may be related to the isomer kinds or used different 
percentages of two usual isomers of CLA (trans- 12, 
cis-9, cis-11). In the study performed by Park et al, the 
isomer with trans-10 and cis-12 of CLA leads to 
increased body ash in mice whereas the isomer cis-9 
with trans-11 had no effect (10). Totally, we can 
conclude the isomer with trans-10 and cis-12 has 
suitable effect on bone metabolism; although, 
predominant isomer in food diet is cis-9 with trans-11 
that 90% isomers in food resources (dairy and meat) is 
this kind of isomer.  
Due to available direct and indirect evidences about 
probable effects of CLA on bone metabolism, we can 
conclude as follows: 
1- Decreasing preinflammatory cytokines such as 
TNF-a, IL-1and IL-6 and increasing 
prostaglandin E2 and osteoclastogenesis 
2- Regulating leptin and decreasing re-absorption 
and increasing bone formation 
3- Regulating serum insulin level 
4- Decreasing serum parathyroid hormone level 
and reducing the osteoclast activity 
Osteoporosis or progressive loss of bone mass is 
happened due to the increase of bone osteoclastic 
activities comparing to its osteoplastic activities. 
However, the aging process is associated with 
increased pre-inflammatory cytokines such as TNF-a, 
IL-1, IL-6 and IL- Beta 1. These cytokines are known 
as main regulators of osteoclastic activities and bone 
re-absorption increase. These cytokines lead to 
increase the expression of cyclo-oxygenase 2 in stroma 
and osteoplastic cells and produce prostaglandin E2 as 
an essential factor in osteoclastogenesis49. In recent 
study, after 12 weeks using of supplementation with 
CLA, the level of TNF-alpha increased significantly 
but the changes of IL-6 was not statistically significant. 
In some surveys, CLA leads to decrease TNF-α 
levels8,48,49. On the other hand, some reports showed 
some increase or any change in TNF-α after using 
CLA49. Such a disharmony in reported results is related 
to the differences between isomers kinds, their purity, 
using different ratios of two isomers, duration of study 
and empirical models.  
Another hypothesis about CLA is that prostaglandin E2 
has involved in secretion of PTH and bone metabolism. 
One of the undesirable effects of estrogen deficiency, 
after menopause, is the negative balance of calcium 
which leads to form secondary hyper-parathyroidism. 
This condition causes to increase bone re-absorption. 
In conducted study on mice with polycystic kidney, 
there was observed the feeding with CLA for 8 weeks, 
compared to control group, in all mice induced the 
reduction of 60% in PTH and the secretion reduction of 
prostaglandin E250. If CLA leads to decrease the 
biosynthesis of prostaglandin E2 in parathyroid tissue, 
there will be a risk to reduce the secretion of PTH. 
However, to prove this hypothesis, there is need to 
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perform some survey in animals and humans. In recent 
study, CLA supplement, compared to the placebo, has 
no effect on the secretion of PTH in postmenopausal 
women. 
One of the limitations in present study is the 
measurement of conjugated linoleic acid levels in 
participants’ serums showing the acceptance rates of 
patients correctly. The numbers of capsules used in this 
study were high because of low purity of CLA (about 
80%). It was suggested, by using of supplements with 
higher purity, the used capsules are reduced in order to 
increase acceptance rates of persons and reduce their 
digestive problems. Due to the counting of capsules, 
the acceptance rates of capsules was 75% in placebo 
group and 85% in the group received supplement.  
One of the main reasons in the various obtained results 
from CLA effects on bone and body composition in 
human and animal studies is using of CLA supplement 
dose. In human studies, used dose is daily between3-6 
g; while in animal studies, used dose is 30 times higher 
than human studies51. If we are used the supplements 
with high purity, we can use upper dose from this 
supplement. Another reason for the lack of CLA 
effects on bone formation markers (such as osteocalcin, 
bone- specific alkaline phosphate) is short duration of 
this research (12 weeks). The time of re-monitoring of 
bone formation markers is 6 months after food and 
medicine interventions and it is suggested to consider 
bone re-absorption markers about 3-6 months after 
food and medicine intervention.   
One of the advantages of this study is to investigate 
postmenopausal women as an aim group because there 
are little studies about this group. It is suggested to 
investigate bone turnover markers in postmenopausal 
women in the first few years after menopause, when 
bone turnover rate is high. As a result, this study 
suggests that consuming 3.2 g CLA supplement 
containing equivalent isomers such as cis-9, trans-10, 
trans-11 and cis-12 with ClarinolTM is safe in this 
particular group for 3 months. 
Conclusion 
Under the conditions tested in this double-blind, 
placebo-controlled trial in postmenopausal women, 3.2 
g CLA isomer blend (50:50% cis-9, trans-11: trans-10, 
cis-12 isomers) did not affect markers of bone 
metabolism and calcium. 
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